MGMT and central nervous system cancer: A recent analysis published in NEMJ in 2017 by Wolfang et al. demonstrated doubling PFS time in MGMT methylated gliomas receiving bevacizumab in monotherapy, versus not methylated ones (2.8 vs. 5.7 months), [26].